Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pyrilamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.72 |
| ▸ | LMNA | P02545 | 5/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.72 |
| ▸ | DRD1 | P21728 | 3/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.72 |
| ▸ | HTR2A | P28223 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrilamine SCHEMBL9666718 | 0.95 | SMN1; SMN2 (0.82) | LMNASMN1; SMN2BLMPMP22HRH1 | |
| Pyrilamine SCHEMBL9666725 | 0.95 | SMN1; SMN2 (0.82) | LMNASMN1; SMN2BLMPMP22HRH1 | |
| Pyrilamine SCHEMBL4945522 | 0.95 | SMN1; SMN2 (0.81) | LMNASMN1; SMN2BLMPMP22HRH1 | |
| Tripelennamine SCHEMBL99166 | 0.91 | LMNA (1.00) | LMNASMN1; SMN2BLMPMP22HRH1 | |
| Pyrilamine SCHEMBL622845 | 0.85 | LMNA (0.95) | LMNASMN1; SMN2BLMPMP22HRH1 | |
| Pyrilamine SCHEMBL29444024 | 0.85 | LMNA (1.00) | LMNASMN1; SMN2BLMPMP22HRH1 | |
| Pyrilamine SCHEMBL19114 | 0.85 | LMNA (1.00) | LMNASMN1; SMN2BLMPMP22HRH1 | |
| Pyrilamine SCHEMBL2406435 | 0.85 | SMN1; SMN2 (1.00) | LMNASMN1; SMN2BLMPMP22HRH1 | |
| Pyrilamine SCHEMBL27430 | 0.85 | SMN1; SMN2 (1.00) | LMNASMN1; SMN2BLMPMP22HRH1 | |
| Pyrilamine SCHEMBL97902 | 0.85 | SMN1; SMN2 (1.00) | LMNASMN1; SMN2BLMPMP22HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | claimed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| US-11738084-B2 | Compositions for transfection of biomolecules into cells | SZATHMARY SUSAN (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-2421952-B1 | COMPOSITIONS FOR TRANSFECTION OF BIOMOLECULES INTO CELLS | GALEN BIO INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20130095124-A1 | COMPOSITIONS FOR TRANSFECTION OF BIOMOLECULES INTO CELLS | SZATHMARY SUSAN (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2012112690-A2 | TARGETING OF THERAPEUTIC DRUGS AND DIAGNOSTIC AGENTS EMPLOYING COLLAGEN BINDING DOMAINS | FABIUS BIOTECHNOLOGY (US) | 2012-08-23 | — | — | WO | disclosed |
| EP-2421952-A2 | COMPOSITIONS FOR TRANSFECTION OF BIOMOLECULES INTO CELLS | Galen Bio, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010123798-A2 | COMPOSITIONS FOR TRANSFECTION OF BIOMOLECULES INTO CELLS | GALENBIO, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | HRH1 1389/4885LMNA 102/4885SMN1; SMN2 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.